Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Review Series

Cancer Immunotherapy

Series edited by Yiping Yang

In the mid-1800s, Rudolf Virchow noted the presence of surfeit inflammatory cells in many tumors. Roughly 50 years later, Paul Ehrlich postulated that the immune system both recognizes and protects against cancer. Since then, researchers have been trying to elucidate the relationship between cancer, inflammation, and the innate and adaptive immune systems, starting with the theory of immunosurveillance introduced by Lewis Thomas and further developed by Sir MacFarlane Burnet. We now know that tumor cells display antigens that are recognized by immune cells, but that anti-tumor immunity can be circumvented directly by tumor cells themselves via a variety of escape mechanisms. The goal of cancer immunotherapy is to mount an effective anti-tumor immune response by repairing, stimulating or, enhancing the immune system’s response to cancer cells. Reviews in this series detail progress in cancer immunoediting, immunosuppressive cells in the tumor microenvironment, cancer-associated inflammation, therapeutic cancer vaccines, genomic approaches in immunotherapy, adoptive transfer of genetically engineered T cells, and checkpoint blockade therapy.

Articles in series

Cancer immunotherapy: harnessing the immune system to battle cancer
Yiping Yang
Yiping Yang
Published September 1, 2015
Citation Information: J Clin Invest. 2015;125(9):3335-3337. https://doi.org/10.1172/JCI83871.
View: Text | PDF

Cancer immunotherapy: harnessing the immune system to battle cancer

  • Text
  • PDF
Abstract

The recent clinical successes of immune checkpoint blockade and chimeric antigen receptor T cell therapies represent a turning point in cancer immunotherapy. These successes also underscore the importance of understanding basic tumor immunology for successful clinical translation in treating patients with cancer. The Reviews in this Review Series focus on current developments in cancer immunotherapy, highlight recent advances in our understanding of basic aspects of tumor immunology, and suggest how these insights can lead to the development of new immunotherapeutic strategies.

Authors

Yiping Yang

×

From mice to humans: developments in cancer immunoediting
Michele W.L. Teng, … , Wolf-Herman Fridman, Mark J. Smyth
Michele W.L. Teng, … , Wolf-Herman Fridman, Mark J. Smyth
Published August 4, 2015
Citation Information: J Clin Invest. 2015;125(9):3338-3346. https://doi.org/10.1172/JCI80004.
View: Text | PDF

From mice to humans: developments in cancer immunoediting

  • Text
  • PDF
Abstract

Cancer immunoediting explains the dual role by which the immune system can both suppress and/or promote tumor growth. Although cancer immunoediting was first demonstrated using mouse models of cancer, strong evidence that it occurs in human cancers is now accumulating. In particular, the importance of CD8+ T cells in cancer immunoediting has been shown, and more broadly in those tumors with an adaptive immune resistance phenotype. This Review describes the characteristics of the adaptive immune resistance tumor microenvironment and discusses data obtained in mouse and human settings. The role of other immune cells and factors influencing the effector function of tumor-specific CD8+ T cells is covered. We also discuss the temporal occurrence of cancer immunoediting in metastases and whether it differs from immunoediting in the primary tumor of origin.

Authors

Michele W.L. Teng, Jerome Galon, Wolf-Herman Fridman, Mark J. Smyth

×

Immunity, inflammation, and cancer: an eternal fight between good and evil
Shabnam Shalapour, Michael Karin
Shabnam Shalapour, Michael Karin
Published September 1, 2015
Citation Information: J Clin Invest. 2015;125(9):3347-3355. https://doi.org/10.1172/JCI80007.
View: Text | PDF

Immunity, inflammation, and cancer: an eternal fight between good and evil

  • Text
  • PDF
Abstract

Cancer development and its response to therapy are strongly influenced by innate and adaptive immunity, which either promote or attenuate tumorigenesis and can have opposing effects on therapeutic outcome. Chronic inflammation promotes tumor development, progression, and metastatic dissemination, as well as treatment resistance. However, cancer development and malignant progression are also associated with accumulation of genetic alterations and loss of normal regulatory processes, which cause expression of tumor-specific antigens and tumor-associated antigens (TAAs) that can activate antitumor immune responses. Although signals that trigger acute inflammatory reactions often stimulate dendritic cell maturation and antigen presentation, chronic inflammation can be immunosuppressive. This antagonism between inflammation and immunity also affects the outcome of cancer treatment and needs to be considered when designing new therapeutic approaches.

Authors

Shabnam Shalapour, Michael Karin

×

Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected
Douglas Marvel, Dmitry I. Gabrilovich
Douglas Marvel, Dmitry I. Gabrilovich
Published July 13, 2015
Citation Information: J Clin Invest. 2015;125(9):3356-3364. https://doi.org/10.1172/JCI80005.
View: Text | PDF

Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected

  • Text
  • PDF
Abstract

Our understanding of the role of myeloid-derived suppressor cells (MDSCs) in cancer is becoming increasingly complex. In addition to their eponymous role in suppressing immune responses, they directly support tumor growth, differentiation, and metastasis in a number of ways that are only now beginning to be appreciated. It is because of this increasingly complex role that these cells may become an important factor in the treatment of human cancer. In this Review, we discuss the most pertinent and controversial issues of MDSC biology and their role in promoting cancer progression and highlight how these cells may be used in the clinic, both as prognostic factors and as therapeutic targets.

Authors

Douglas Marvel, Dmitry I. Gabrilovich

×

Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages
Stefano Ugel, … , Susanna Mandruzzato, Vincenzo Bronte
Stefano Ugel, … , Susanna Mandruzzato, Vincenzo Bronte
Published September 1, 2015
Citation Information: J Clin Invest. 2015;125(9):3365-3376. https://doi.org/10.1172/JCI80006.
View: Text | PDF

Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages

  • Text
  • PDF
Abstract

The generation of an inflammatory environment is favorable and often decisive for the growth of both primary tumors and metastases. Tumor cells either express membrane molecules or release tumor-derived soluble factors able to alter myelopoiesis. Tumor-reprogrammed myeloid cells not only create a tolerogenic environment by blocking T cell functions and proliferation, but also directly drive tumor growth by promoting cancer stemness, angiogenesis, stroma deposition, epithelial-to-mesenchymal transition, and metastasis formation. In this Review, we discuss the interplay between immunosuppressive and protumoral myeloid cells and detail their immune-regulatory mechanisms, the molecular pathways involved in their differentiation, as well as their potential role as prognostic and diagnostic biomarkers and prospective targets for innovative approaches to treat tumor-bearing hosts.

Authors

Stefano Ugel, Francesco De Sanctis, Susanna Mandruzzato, Vincenzo Bronte

×

Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade
Elizabeth Buchbinder, F. Stephen Hodi
Elizabeth Buchbinder, F. Stephen Hodi
Published September 1, 2015
Citation Information: J Clin Invest. 2015;125(9):3377-3383. https://doi.org/10.1172/JCI80012.
View: Text | PDF

Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade

  • Text
  • PDF
Abstract

The relationship between cancer and the immune system is complex and provides unique therapeutic opportunities. Cytotoxic T lymphocyte antigen-4 (CTLA-4) is a regulatory molecule that suppresses T cell effector function following initial activation by costimulatory signals. Fully human monoclonal antibodies targeting CTLA-4 have been shown to increase T cell function and antitumor responses in patients with advanced metastatic melanoma. Responses observed with such immune checkpoint therapy can follow a different pattern from that seen with cytotoxic chemotherapy or targeted therapy and may continue after therapy is discontinued. In addition, the toxicities that are associated with anti–CTLA-4 therapy may differ from those of conventional therapies and consist of inflammatory events in parts of the body that do not contain cancerous cells. Early recognition of these inflammatory events and intervention is important, and the identification of predictive biomarkers continues to be an unfulfilled need in the field of immunotherapy. Combinatorial approaches with targeted therapies, radiation therapy, chemotherapy, or other immune checkpoint agonists/antagonists have the potential to increase the efficacy of CTLA-4 blockade.

Authors

Elizabeth Buchbinder, F. Stephen Hodi

×

Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future
Lieping Chen, Xue Han
Lieping Chen, Xue Han
Published September 1, 2015
Citation Information: J Clin Invest. 2015;125(9):3384-3391. https://doi.org/10.1172/JCI80011.
View: Text | PDF

Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future

  • Text
  • PDF
Abstract

Major progress has been made toward our understanding of the programmed death-1/programmed death ligand-1 (PD-1/PD-L1) pathway (referred to as the PD pathway). mAbs are already being used to block the PD pathway to treat human cancers (anti-PD therapy), especially advanced solid tumors. This therapy is based on principles that were discovered through basic research more than a decade ago, but the great potential of this pathway to treat a broad spectrum of advanced human cancers is just now becoming apparent. In this Review, we will briefly review the history and development of anti-PD therapy, from the original benchwork to the most up-to-date clinical results. We will then focus the discussion on three basic principles that define this unique therapeutic approach and highlight how anti-PD therapy is distinct from other immunotherapeutic approaches, namely tumor site immune modulation, targeting tumor-induced immune defects, and repairing ongoing (rather than generating de novo) tumor immunity. We believe that these fundamental principles set the standard for future immunotherapies and will guide our efforts to develop more efficacious and less toxic immune therapeutics to treat human cancers.

Authors

Lieping Chen, Xue Han

×

CAR therapy: the CD19 paradigm
Michel Sadelain
Michel Sadelain
Published September 1, 2015
Citation Information: J Clin Invest. 2015;125(9):3392-3400. https://doi.org/10.1172/JCI80010.
View: Text | PDF

CAR therapy: the CD19 paradigm

  • Text
  • PDF
Abstract

Twenty-five years after its inception, the genetic engineering of T cells is now a therapeutic modality pursued at an increasing number of medical centers. This immunotherapeutic strategy is predicated on gene transfer technology to instruct T lymphocytes to recognize and reject tumor cells. Chimeric antigen receptors (CARs) are synthetic receptors that mediate antigen recognition, T cell activation, and — in the case of second-generation CARs — costimulation to augment T cell functionality and persistence. We demonstrated over a decade ago that human T cells engineered with a CD19-specific CAR eradicated B cell malignancies in mice. Several phase I clinical trials eventually yielded dramatic results in patients with leukemia or lymphoma, especially acute lymphoblastic leukemia (ALL). This review recounts the milestones of CD19 CAR therapy and summarizes lessons learned from the CD19 paradigm.

Authors

Michel Sadelain

×

Therapeutic cancer vaccines
Cornelis J.M. Melief, … , Ferry Ossendorp, Sjoerd H. van der Burg
Cornelis J.M. Melief, … , Ferry Ossendorp, Sjoerd H. van der Burg
Published July 27, 2015
Citation Information: J Clin Invest. 2015;125(9):3401-3412. https://doi.org/10.1172/JCI80009.
View: Text | PDF

Therapeutic cancer vaccines

  • Text
  • PDF
Abstract

The clinical benefit of therapeutic cancer vaccines has been established. Whereas regression of lesions was shown for premalignant lesions caused by HPV, clinical benefit in cancer patients was mostly noted as prolonged survival. Suboptimal vaccine design and an immunosuppressive cancer microenvironment are the root causes of the lack of cancer eradication. Effective cancer vaccines deliver concentrated antigen to both HLA class I and II molecules of DCs, promoting both CD4 and CD8 T cell responses. Optimal vaccine platforms include DNA and RNA vaccines and synthetic long peptides. Antigens of choice include mutant sequences, selected cancer testis antigens, and viral antigens. Drugs or physical treatments can mitigate the immunosuppressive cancer microenvironment and include chemotherapeutics, radiation, indoleamine 2,3-dioxygenase (IDO) inhibitors, inhibitors of T cell checkpoints, agonists of selected TNF receptor family members, and inhibitors of undesirable cytokines. The specificity of therapeutic vaccination combined with such immunomodulation offers an attractive avenue for the development of future cancer therapies.

Authors

Cornelis J.M. Melief, Thorbald van Hall, Ramon Arens, Ferry Ossendorp, Sjoerd H. van der Burg

×

Tumor neoantigens: building a framework for personalized cancer immunotherapy
Matthew M. Gubin, … , Elaine R. Mardis, Robert D. Schreiber
Matthew M. Gubin, … , Elaine R. Mardis, Robert D. Schreiber
Published August 10, 2015
Citation Information: J Clin Invest. 2015;125(9):3413-3421. https://doi.org/10.1172/JCI80008.
View: Text | PDF

Tumor neoantigens: building a framework for personalized cancer immunotherapy

  • Text
  • PDF
Abstract

It is now well established that the immune system can recognize developing cancers and that therapeutic manipulation of immunity can induce tumor regression. The capacity to manifest remarkably durable responses in some patients has been ascribed in part to T cells that can (a) kill tumor cells directly, (b) orchestrate diverse antitumor immune responses, (c) manifest long-lasting memory, and (d) display remarkable specificity for tumor-derived proteins. This specificity stems from fundamental differences between cancer cells and their normal counterparts in that the former develop protein-altering mutations and undergo epigenetic and genetic alterations, resulting in aberrant protein expression. These events can result in formation of tumor antigens. The identification of mutated and aberrantly expressed self-tumor antigens has historically been time consuming and laborious. While mutant antigens are usually expressed in a tumor-specific manner, aberrantly expressed antigens are often shared between cancers and, therefore, in the past, have been the major focus of therapeutic cancer vaccines. However, advances in next-generation sequencing and epitope prediction now permit the rapid identification of mutant tumor neoantigens. This review focuses on a discussion of mutant tumor neoantigens and their use in personalizing cancer immunotherapies.

Authors

Matthew M. Gubin, Maxim N. Artyomov, Elaine R. Mardis, Robert D. Schreiber

×

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts